CDKN1B and hepatocellular carcinoma: Since miR-494 showed the highest activity in a colony forming unit assay and increased cell cycle progression through MCC targeting, the antitumor potential of miR-494 antagonist molecules was tested in Myc-driven HCC bearing mice showing decreased tumor burden associated with increased p27 and MCC protein levels [16].